Table 1.

Clinical Summary of Patient Samples

	Repository (n = 63)	Sequenced Subset (n = 16)
Standard-of-care resection	34 (54%)	6 (38%)
Trametinib trial	22 (35%)	10 (63%)
Pembrolizumab trial	7 (11%)	-
Treatment-naive	45 (71%)	14 (88%)
Post-treatment	15 (24%)	-
Relapse	3 (5%)	2 (13%)
I	3 (5%)	-
II	2 (3%)	-
III	12 (19%)	3 (19%)
IV	45 (71%)	13 (81%)
Below 40	4 (6%)	2 (13%)
40–59	22 (35%)	6 (38%)
60–79	29 (46%)	7 (44%)
Over 80	8 (13%)	1 (6%)
Male	46 (73%)	12 (75%)
Female	17 (27%)	4 (25%)

Overall, 63 PDXs were generated from 53 patients. In some cases, multiple PDXs were derived from the same patient at various time points. Numbers (n) reflect number of xenografts associated. Refer to Table S1 for additional information